Literature DB >> 9589472

Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas.

H Koizumi1, M Morita, S Mikami, E Shibayama, T Uchikoshi.   

Abstract

The Trk family of tyrosine protein kinase receptors plays a significant role in the development and maintenance of neural tissues. It has been recently shown that Trk receptors are also expressed by a wide range of normal non-neuronal tissues in humans in a cell type-specific manner. In the present study, the expression patterns of TrkA in 337 non-neuronal invasive carcinomas of 15 different human tissues were investigated immunohistochemically. Overall, 133 (39%), 101 (30%) and 103 (31%) tumors exhibited strong, moderate and no TrkA immunoreactivity, respectively. Esophageal and thyroid carcinomas expressed high levels of TrkA, whereas the levels in gastric and colon cancers were low. TrkA expression was detected not only in carcinomas originating from TrkA-positive normal counterpart tissues, including the esophagus, breast, lung and uterus, but also in those from TrkA-negative tissues/cells of the thyroid, liver and ovary. Immunostaining for nerve growth factor-beta, the specific ligand for TrkA, in esophageal and breast carcinomas demonstrated its immunoreactivity in stromal fibroblasts and some TrkA-expressing tumor cells. These results suggest that paracrine/autocrine regulation via stromal/tumoral NGF-tumoral TrkA interaction may be involved in the growth of certain non-neuronal carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9589472     DOI: 10.1111/j.1440-1827.1998.tb03877.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

1.  Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.

Authors:  John L Marshall; Hedy Kindler; John Deeken; Pankaj Bhargava; Nicholas J Vogelzang; Naiyer Rizvi; Taina Luhtala; Stacy Boylan; Margaret Dordal; Philmore Robertson; Michael J Hawkins; Mark J Ratain
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

2.  Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.

Authors:  G W Reuther; Q T Lambert; M A Caligiuri; C J Der
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

4.  Expression of NGF family and their receptors in gastric carcinoma: a cDNA microarray study.

Authors:  Jian-Jun Du; Ke-Feng Dou; Shu-You Peng; Bing-Zhi Qian; Hua-Sheng Xiao; Feng Liu; Wei-Zhong Wang; Wen-Xian Guan; Zhi-Qing Gao; Ying-Bin Liu; Ze-Guang Han
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

5.  Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis.

Authors:  Fiona Oakley; Nathan Trim; Christothea M Constandinou; Weilan Ye; Alane M Gray; Gretchen Frantz; Kenneth Hillan; Tim Kendall; R Christopher Benyon; Derek A Mann; John P Iredale
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma.

Authors:  Guido Rasi; Annalucia Serafino; Lia Bellis; Maria Teresa Lonardo; Federica Andreola; Manuela Zonfrillo; Giovanni Vennarecci; Pasquale Pierimarchi; Paola Sinibaldi Vallebona; Giuseppe Maria Ettorre; Eugenio Santoro; Claudio Puoti
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

7.  Peptidergic innervation of human esophageal and cardiac carcinoma.

Authors:  Shuang-Hong Lü; Yan Zhou; Hai-Ping Que; Shao-Jun Liu
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases.

Authors:  Melinda Wuest; Justin J Bailey; Jennifer Dufour; Darryl Glubrecht; Vanessa Omana; Tom H Johnston; Jonathan M Brotchie; Ralf Schirrmacher
Journal:  EJNMMI Res       Date:  2022-07-30       Impact factor: 3.434

9.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

10.  Characterization of TRKA signaling in acute myeloid leukemia.

Authors:  Shelley M Herbrich; Sankaranarayanan Kannan; Riitta M Nolo; Marisa Hornbaker; Joya Chandra; Patrick A Zweidler-McKay
Journal:  Oncotarget       Date:  2018-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.